Results 61 to 70 of about 4,484 (145)

Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada

Canadian Journal of Gastroenterology and Hepatology, 2015
BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to ...
Sergio M Borgia, Adenike Rowaiye
doaj   +1 more source

Changes in serum myostatin levels among patients with type C liver cirrhosis treated with direct‐acting antivirals

Hepatology Research, Volume 55, Issue 5, Page 631-637, May 2025.
Direct‐acting antiviral treatment for patients with type C liver cirrhosis not only improves the liver function, but also reduces the myostatin level, which is associated with muscle atrophy. Therefore, antiviral therapy may improve sarcopenia associated with chronic liver disease.
Tomoyuki Suehiro, Hideko Kozuru, Kosuke Matusmoto, Yuki Kugiyama, Yasuhide Motoyoshi, Akira Saeki, Shinya Nagaoka, Kazumi Yamasaki, Atsumasa Komori, Hiroshi Yatsuhashi   +9 more
wiley   +1 more source

Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C

ClinicoEconomics and Outcomes Research, 2018
Katherine Heath1,2 1Mathematical Ecology Research Group, Department of Zoology, University of Oxford, Oxford OX1 3PS, UK; 2New College, Oxford OX1 3BN, UK Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the ...
Heath K
doaj  

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant

Annals of Hepatology, 2017
Introduction: Recurrence of HCV infection in patients with chronic hepatitis C virus (HCV) at the time of liver transplantation is nearly universal and reduces the likelihood of graft and patient survival.
Eric M. Yoshida, Paul Kwo, Kosh Agarwal, Christophe Duvoux, François Durand, Markus Peck-Radosavljevic, Leslie Lilly, Bernard Willems, Hugo Vargas, Princy Kumar, Robert S. Brown Jr., Yves Horsmans, Shampa De-Oertel, Sarah Arterburn, Hadas Dvory-Sobol, Diana M. Brainard, John G. McHutchison, Norah Terrault, Mario Rizzetto, Beat Müllhaupt   +19 more
doaj   +1 more source

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source

An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences

Pathogens
Direct-acting antivirals (DAAs) revolutionized the therapeutics of chronic hepatitis C. The emergence and transmission of HCV variants with resistance-associated substitutions (RASs) can undermine HCV treatment.
Roaa Khalil, Kholoud Al-Mahzoum, Muna Barakat, Malik Sallam   +3 more
doaj   +1 more source

Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

SAGE Open Medicine, 2018
Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or ...
Mete Akin, Osman Cagin Buldukoglu, Haydar Adanir, Inci Suleymanlar, Dinc Dincer, Bulent Yildirim   +5 more
doaj   +1 more source

Concomitant Treatment of Hepatitis C Virus and Diffuse Large B-Cell Lymphoma with Direct-Acting Antivirals in HIV Coinfection: A Case Report

Journal of the International Association of Providers of AIDS Care, 2019
This report describes a case of concomitant treatment of advanced diffuse large B-cell lymphoma with chemoimmunotherapy along with direct-acting antivirals for hepatitis C virus in a patient coinfected with HIV.
Alyssa Gallipani PharmD, BCACP, Agnes Cha PharmD, AAHIVP, BCACP, Leonard Berkowitz MD, Anjali Bakshi MD   +3 more
doaj   +1 more source

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C

Hepatic Medicine: Evidence and Research, 2017
Paul H Naylor , Milton Mutchnick Department of Internal Medicine/Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA Abstract: African Americans (AA) in the US are twice as likely to be infected with hepatitis C virus (HCV)
Naylor PH, Mutchnick M
doaj  

Ledipasvir [PDF]

, 2020
openaire   +1 more source